HER2 is the only molecular marker in breast cancer to make its way into clinical practice. Th is protein kinase receptor has become a thera peutical target since the development by Genen tech (South San Francisco, CA, USA) of anti-HER2 monoclonal antibodies. But do HER2-positive breast cancers form a homogeneous group of tumors? Th is question is addressed by Staaf and colleagues in this issue of Breast Cancer Research [1] .
Amplifi cation and overexpression of the HER2 gene in about 15% of breast cancers were originally discovered in 1987 [2, 3] , in the early days of molecular oncology. Since that time, technologies have changed, the human genome has been sequenced, and DNA arrays allow investigators to address genetic changes on a genome-wide scale. Our views of breast cancer and of the sequence of oncogenic changes that govern its emergence have changed considerably as well.
For HER2-positive breast cancers, the introduction of trastuzumab has been a radical change, improving the outcome of these patients substantially. Th is success has contributed to the defi nition of a HER2-positive breast cancer subclass. However, a number of patients show either primary or acquired resistance to this therapy. Th is clinical reality motivated the group of Ake Borg [1] at the University of Lund, Sweden, to address the question of the biological homogeneity of HER2-positive tumors. To do this, they collaborated with colleagues from the University of Iceland in the collection of a large (200) series of primary HER2-positive breast cancers, which they characterized by CGH (comparative genomic hybridi zation) using tiling-path BAC (bacterial artifi cial chromosome) array. Th ese data were related to an external dataset comprising CNA (copy number alteration) profi les from 554 HER2-negative breast tumors. Th e principal fi nding of this work is that HER2-positive breast cancers present a large diversity of anomalies aff ecting most of the genome. Th ey show, apart from HER2 amplifi cation, high-level amplifi cation at multiple sites and a number of these amplifi cations correspond to known oncogenes (FGFR1, MYC, CCND1, and ZNF217). Some apparently distinguishing features of HER2-positive breast tumors are the so-called fi restorm patterns. Firestorms correspond to multiple focal amplifi cations of neighboring loci. Th ese occurred on a number of chromosomal arms but principally at 17q. Such patterns concentrated on the chromosomal arm carrying the HER2 locus raise interesting questions about the mechanism at work. Th e fi rst idea that comes to mind is that it may correspond to a cooperative mechanism resulting in the selection of secondary mutations. As is often the case, the reality is more complex since only a few of these fi restorm amplicons at 17q were recurrent. Th e second important fi nding concerns amplifi cation of the HER2 locus, which can be split into two subsets: (a) narrow amplicons (86 kb in its smallest form) that centered around HER2 and that comprise 6 to 10 genes, of which 4 showed recurrent overexpression, and (b) a large amplicon (1.1 Mb) starting centromeric to HER2 and extending telomeric to the TOP2A gene. Th e abrupt break downstream of TOP2A is a clear indication of a coselection. Th is work shows that these two amplifi cation patterns point to diff erent breast cancer subsets. Th e small amplicon is found in estrogen receptor (ER)- − showed higher ploidy indices and profi les that were more rearranged than those of their ER + counterparts. Th is work parallels and complements an earlier study by the same group [4] ; that study was based on expression profi ling and aimed at determining a molecular predictor of bad outcome in HER2-positive tumors. A total of 58 HER2-positive breast cancers were analyzed. By unsupervised analysis, three clusters of tumors, one of which presented a substantially worse outcome, were delineated. A 158-gene prognostic predictor specifi c to HER2-positive breast cancer was proposed.
Altogether, these data bring clear evidence that HER2-positive breast tumors do not form a homogeneous biological entity. Th is was already apparent in molecular subtypes defi ned by unsupervised expression profi ling classifi cation. Four to fi ve molecular subtypes, one of which was the ERBB2 subtype, were described [5] . It was soon apparent that this ERBB2 subtype was not exclusively composed of HER2-amplifi ed breast tumors and, conversely, that HER2-positive tumors clustered in other molecular subgroups. Th is was very clearly confi rmed by Weigelt and colleagues [6] in a recent study (2010) comparing the relative effi ciency of two singlesample predictors (SSPs). Th ere are repeated calls for a refi ned molecular classifi cation, but there is a reasonable likelihood that it would not delineate a subgroup corresponding to HER2-positive cancers.
If HER2-positive tumors do not correspond to a biological subclass of breast cancer, they defi ne a clinical subset of patients. Th is determines its importance and the huge eff orts that are deployed to better characterize them. It must be mentioned that in the framework of the International Cancer Genome Consortium (ICGC), which aims at sequencing the genome of 500 tumors of at least 50 cancer types, France has decided to take HER2-positive breast cancer as a target. Th e genomic heterogeneity revealed by the work of Staaf and colleagues [1] calls for further work in order to determine the lines along which we will delineate the diff erent subsets of HER2-positive breast cancers. It will be interesting, in particular, to see whether it is possible to outline a coherent scheme of co-occurring amplifi cations. If such a scheme exists, it may be a good basis on which to defi ne complementary therapies by targeting genes coamplifi ed with HER2. Th ere are great expectations that the ICGC program will bring answers to these questions.
Abbreviations ER, estrogen receptor; ICGC, International Cancer Genome Consortium.
